Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$2.64 -37.9%	$1.36	$0.46 ▼ $7.49	$14.12M	-0.1	19.99 million shs	13.26 million shs
DRRX DURECT	$1.92 +1.1%	$1.10	$0.48 ▼ $2.64	$59.62M	0.83	3.11 million shs	416,978 shs
KPTI Karyopharm Therapeutics	$6.30 +4.7%	$4.53	$3.51 ▼ $16.95	$54.63M	0.28	201,302 shs	112,192 shs
PHGE BiomX	$0.54 -26.9%	$0.46	$0.34 ▼ $2.40	$14.51M	1.42	347,190 shs	53,300 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	0.00%	+89.93%	+50.86%	+197.33%	-14.84%
DRRX DURECT	0.00%	+0.52%	+226.75%	+252.94%	+43.82%
KPTI Karyopharm Therapeutics	0.00%	+6.42%	+42.21%	+37.25%	-48.10%
PHGE BiomX	0.00%	-2.70%	+24.42%	+5.26%	-63.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APM Aptorum Group	0.7329 of 5 stars	0.0	2.0	0.0	3.9	1.7	0.0
DRRX DURECT	2.2138 of 5 stars	0.0	5.0	4.4	4.2	0.0	0.0
KPTI Karyopharm Therapeutics	3.8222 of 5 stars	3.4	0.0	4.6	2.0	2.5	0.6
PHGE BiomX	2.0869 of 5 stars	3.5	0.0	0.0	1.1	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APM Aptorum Group	0.00	N/A	N/A	N/A
DRRX DURECT	2.00	Hold	N/A	N/A
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$34.00	439.68% Upside
PHGE BiomX	3.00	Buy	$21.00	3,788.89% Upside

Current Analyst Ratings Breakdown

Latest PHGE, APM, KPTI, and DRRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$42.00 ➝ $25.00
7/29/2025	DRRX DURECT	Northland Capmk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APM Aptorum Group	$430K	32.85	N/A	N/A	$2.20 per share	1.20
DRRX DURECT	$1.66M	35.98	N/A	N/A	$0.11 per share	17.45
KPTI Karyopharm Therapeutics	$145.24M	0.38	N/A	N/A	($27.55) per share	-0.23
PHGE BiomX	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APM Aptorum Group	-$4.27M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
DRRX DURECT	-$8.32M	-$0.10	N/A	N/A	N/A	-96.19%	-259.16%	-71.78%	11/12/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$14.59	N/A	N/A	N/A	-90.02%	N/A	-84.28%	11/4/2025 (Estimated)
PHGE BiomX	-$28.32M	-$1.36	N/A	N/A	N/A	N/A	-127.82%	-56.50%	N/A

Latest PHGE, APM, KPTI, and DRRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	DRRX DURECT	-$0.13	-$0.07	+$0.06	-$0.07	$0.32 million	$0.45 million
8/11/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.80	-$4.32	-$0.52	-$4.32	$37.92 million	$37.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
DRRX DURECT	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APM Aptorum Group	N/A	0.22	0.22
DRRX DURECT	N/A	0.98	0.95
KPTI Karyopharm Therapeutics	N/A	0.99	0.94
PHGE BiomX	0.51	2.84	2.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APM Aptorum Group	3.80%
DRRX DURECT	28.03%
KPTI Karyopharm Therapeutics	66.44%
PHGE BiomX	40.57%

Insider Ownership

Company	Insider Ownership
APM Aptorum Group	63.99%
DRRX DURECT	3.20%
KPTI Karyopharm Therapeutics	2.98%
PHGE BiomX	1.17%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APM Aptorum Group	30	5.35 million	1.93 million	Not Optionable
DRRX DURECT	80	31.05 million	30.06 million	Optionable
KPTI Karyopharm Therapeutics	380	8.67 million	8.41 million	Optionable
PHGE BiomX	120	26.53 million	44.04 million	Not Optionable

PHGE, APM, KPTI, and DRRX Headlines

Recent News About These Companies

BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis

August 19, 2025 | globenewswire.com

BiomX Posts Q2 Loss With 14% Cost Drop

August 14, 2025 | aol.comA

BiomX Inc. (PHGE) Q2 2025 Earnings Call Transcript

August 13, 2025 | seekingalpha.com

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

August 13, 2025 | globenewswire.com

What to Expect from BiomX's Earnings

August 12, 2025 | benzinga.com

BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

August 6, 2025 | globenewswire.com

BiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapy

July 14, 2025 | investing.com

BiomX Shares Surge 60% Following Start of Phase 2b Trial for Cystic Fibrosis Treatment

July 14, 2025 | msn.com

PHGE | BiomX Inc. Stock Overview (U.S.: NYSE American) | Barron's

July 14, 2025 | barrons.com

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

July 14, 2025 | globenewswire.com

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

July 8, 2025 | globenewswire.com

BiomX Inc. to Present Positive Phase 2 Results for BX211 at Biomed Israel 2025 Conference

May 21, 2025 | nasdaq.com

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

May 19, 2025 | globenewswire.com

BiomX Inc. (AMEX:PHGE) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

May 15, 2025 | globenewswire.com

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

May 8, 2025 | globenewswire.com

BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

April 18, 2025 | zacks.com

BiomX announces going concern qualification from independent audit

April 1, 2025 | markets.businessinsider.com

BiomX target adjusted to $21 from $2 at H.C. Wainwright

April 1, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHGE, APM, KPTI, and DRRX Company Descriptions

Aptorum Group NASDAQ:APM

$2.64 -1.61 (-37.88%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.54 -0.10 (-3.64%)

As of 08/22/2025 08:00 PM Eastern

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

DURECT NASDAQ:DRRX

$1.92 +0.02 (+1.05%)

As of 08/22/2025 04:00 PM Eastern

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Karyopharm Therapeutics NASDAQ:KPTI

$6.30 +0.28 (+4.65%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.38 +0.08 (+1.27%)

As of 08/22/2025 07:50 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

BiomX NYSEMKT:PHGE

$0.54 -0.20 (-26.93%)

Closing price 08/22/2025 03:57 PM Eastern

Extended Trading

$0.54 +0.00 (+0.56%)

As of 08/22/2025 08:00 PM Eastern

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time